Kyowa Kirin plans Japan pegfilgrastim filing on good Phase III data, but biosimilar G-CSFs loom
This article was originally published in Scrip
Executive Summary
Kyowa Hakko Kirin plans to make a Japanese approval filing sometime this year for KRN125, its pegylated version of the granulocyte colony-stimulating factor (G-CSF) filgrastim, following positive top line results in two local Phase III trials.